Wellgistics Targets $70B Market Breakthrough Addressing Ozempic / GLP-1 Muscle Loss with Forzet(TM)

Rhea-AI Summary

Wellgistics Health (NASDAQ:WGRX) launched Forzet, a medical food for the dietary management of muscle loss associated with GLP-1 agonist weight-loss therapies, on March 9, 2026. Forzet is OTC, not an FDA-approved drug, and was evaluated in multiple controlled clinical studies in Europe.

The company will distribute Forzet through its affiliated pharmacy and select Wellgistics Pharmacy Network members and plans to promote it via EinsteinRx™ point-of-sale pop-ups and expanded DTC telehealth/pharmacy channels.

Positive

• Product launch of Forzet targeting GLP-1-related muscle loss
• Forzet evaluated in multiple controlled clinical studies in Europe
• Distribution via affiliated pharmacy and Wellgistics Pharmacy Network
• Promotion integrated with EinsteinRx™ point-of-sale hub technology

Negative

• Forzet is not an FDA-approved drug and is marketed as a medical food
• Initial availability limited to affiliated pharmacy and select network members

News Market Reaction – WGRX

+5.81%

2 alerts

+5.81% News Effect

+9.2% Peak Tracked

+$813K Valuation Impact

$15M Market Cap

2K Volume

On the day this news was published, WGRX gained 5.81%, reflecting a notable positive market reaction. Argus tracked a peak move of +9.2% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $813K to the company's valuation, bringing the market cap to $15M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

GLP-1 market 2025: $70B GLP-1 market 2030: $201B

2 metrics

GLP-1 market 2025 $70B GLP-1 agonist market size in 2025 per Grandview Research

GLP-1 market 2030 $201B Projected GLP-1 agonist market size in 2030 per Grandview Research

Market Reality Check

Price: $0.1747 Vol: Volume 2,905,623 is 1.77x...

high vol

$0.1747 Last Close

Volume Volume 2,905,623 is 1.77x 20-day average 1,641,096, indicating elevated pre-news activity. high

Technical Shares at 0.1651 are trading well below 200-day MA of 0.83 and 97.65% under the 52-week high.

Peers on Argus

WGRX shows a -14.46% move versus mostly positive peers like SSY (+9.31%), HKPD (...

WGRX shows a -14.46% move versus mostly positive peers like SSY (+9.31%), HKPD (+6.44%) and HITI (+1.22%), suggesting stock-specific dynamics rather than a sector-wide trend.

Historical Context

5 past events · Latest: Mar 05 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 05	Blockchain tracking build	Positive	-9.2%	Selected five blockchain platforms to build PharmacyChain™ serialization system.
Feb 23	HaaS partnership	Positive	+9.8%	Expanded Datavault AI partnership for Healthcare as a Service smart contracts.
Feb 18	Mental health AI deal	Positive	+0.3%	Strategic investment in mental health AI startup tied to EinsteinRx™ platform.
Feb 11	Telehealth expansion	Positive	+4.0%	Expanded Tollo Health partnership adding telehealth and mental health AI services.
Feb 09	NFL partnership	Positive	-1.6%	NFL Alumni Health deal to deploy EinsteinRx™ and PharmacyChain™ nationwide.

Pattern Detected

Recent news has mostly been strategic and positive, yet price reactions are mixed, with several selloffs on otherwise constructive announcements.

Recent Company History

Over the last month, Wellgistics announced multiple initiatives around its EinsteinRx™ AI hub and PharmacyChain™ platform, including an NFL Alumni Health partnership leveraging 6,500 pharmacies and a Tollo Health telehealth expansion. It moved into mental health AI and outlined blockchain-based drug serialization efforts. Price reactions to these updates ranged from about -9% to nearly +10%, indicating inconsistent alignment between positive strategic news and short-term trading. The current Forzet™ launch adds a GLP‑1‑focused medical food layer to this evolving ecosystem.

Market Pulse Summary

The stock moved +5.8% in the session following this news. A strong positive reaction aligns with the...

Analysis

The stock moved +5.8% in the session following this news. A strong positive reaction aligns with the large GLP-1 addressable market, cited at $70B in 2025 growing to $201B by 2030. Historically, WGRX’s strategic announcements have produced mixed but sometimes sizable moves, suggesting traders respond to perceived execution potential. Investors would likely watch how Forzet adoption through the Wellgistics Pharmacy Network and EinsteinRx integration evolves, as well as balance-sheet developments from recent financings and settlements that could still influence future dilution and risk perceptions.

Key Terms

glp-1 agonist, medical food, cGMP, copd, +3 more

7 terms

glp-1 agonist medical

"Forzet is being launched initially to physicians and pharmacists who prescribe and dispense GLP-1 agonist drugs."

A GLP‑1 agonist is a drug that mimics a naturally occurring hormone involved in controlling blood sugar and appetite; think of it as a spare key that fits a body’s lock to trigger signals reducing blood sugar and slowing hunger. For investors, these medicines matter because they can treat common, long‑term conditions like diabetes and obesity, drive large prescription sales, and face close regulatory scrutiny and competitive innovation that affect company revenues and valuations.

medical food medical

"today announced the launch of medical food Forzet™ for the dietary management of muscle loss"

Specialized nutritional products designed to be used under a health professional’s supervision to manage specific medical conditions that have unique dietary needs. Think of them as a tailored meal plan in a bottle or package: not a medicine and not an everyday food, but a regulated product intended to address nutrition gaps tied to a disease. Investors track them because they follow different approval, labeling, and reimbursement rules, which affect market size and sales channels.

cGMP technical

"and -stringent cGMP manufacturing requirements."

cGMP (current Good Manufacturing Practice) are government-enforced quality standards that manufacturers must follow to ensure drugs, medical devices, and related products are made consistently, safely, and meet specified quality tests. For investors, cGMP compliance is like a restaurant passing health inspections: it reduces the risk of product recalls, regulatory fines, or production stoppages that can hurt revenue and company value, and it supports market access and long-term trust.

copd medical

"including in patients with Type 2 diabetes, heart failure and COPD in Europe."

Chronic obstructive pulmonary disease (COPD) is a long-term lung condition that progressively narrows airways and reduces the ability to breathe, causing persistent cough, shortness of breath and fatigue. It matters to investors because a large and growing patient population creates steady demand for drugs, medical devices and care services, influences healthcare spending and regulatory decisions, and offers clear market opportunities—similar to a leaking engine that requires ongoing fixes and replacement parts.

telehealth medical

"as we build out our own telehealth customer base where we can more fully service patients"

Telehealth is the delivery of healthcare services and consultations remotely using video calls, phone, text messaging, or connected devices to monitor and transmit medical information. It matters to investors because it can reshape how patients access care, lower costs, and create new revenue streams or risks for healthcare providers, insurers and technology companies—similar to how online banking changed financial services—while also exposing businesses to reimbursement and regulatory shifts.

blockchain technical

"patented blockchain-enabled smart contracts platform PharmacyChain™"

A blockchain is a digital record-keeping system that securely stores information across many computers, making it difficult to alter or tamper with. Think of it like a shared, unchangeable ledger that everyone can see and verify, ensuring transparency and trust. For investors, this technology offers a way to securely track transactions and assets without relying on a central authority, potentially reducing costs and increasing security.

over the counter regulatory

"Forzet is not an FDA-approved drug, is available over the counter and does not require a prescription."

Over the counter describes securities, like stocks or bonds, that are bought and sold directly between dealers or through a dealer network rather than on a formal stock exchange. Think of it as a farmers’ market versus a supermarket: prices can be less visible, trades may be slower and riskier, and rules can be looser, so investors should expect wider price swings, lower liquidity, and potentially greater difficulty buying or selling large positions.

AI-generated analysis. Not financial advice.

• GLP-1 agonist market expected to grow from $70B in 2025 to $201B in 2030¹

• Proprietary Forzet formulation provides pharmacists, physicians and patients with unique solution for GLP-1 drugs' primary side effect

• Forzet targeting preservation of muscle while on GLP-1 agonist therapy to facilitate continued patient adherence and muscle redevelopment following therapy discontinuation to help mitigate weight regain

TAMPA, FLORIDA / ACCESS Newswire / March 9, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics") , a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx^™ into its patented blockchain-enabled smart contracts platform PharmacyChain^™, today announced the launch of medical food Forzet™ for the dietary management of muscle loss associated with weight loss therapies. Forzet is being launched initially to physicians and pharmacists who prescribe and dispense GLP-1 agonist drugs. Forzet's proprietary formulation has been evaluated in multiple controlled clinical studies, including in patients with Type 2 diabetes, heart failure and COPD in Europe. Forzet will initially be be made available through the Company's affiliated pharmacy and select members of the Wellgistics Pharmacy Network. Forzet is classified as a medical food intended for the dietary management of muscle loss associated with weight loss therapies under physician supervision. Forzet is not an FDA-approved drug, is available over the counter and does not require a prescription.

"Forzet is indicated for the dietary management of muscle loss associated with weight loss therapies," said Prashant Patel, RPh, President & Interim-CEO of Wellgistics Health. "GLP-1 agonist drugs such as Ozempic^®, Wegovy^®, Mounjaro^® and others are members of the fastest growing class of drugs worldwide because of myriad benefits that result from losing weight. While the benefits of the weight loss associated with GLP-1 agonist therapy can no longer be denied, it remains the case that a significant amount of that weight loss comes from loss of muscle. As such, the Company believes there may be a significant market opportunity for a medical food product that distinguishes itself from dietary supplements by virtue of its extensive clinical data package in sarcopenia associated with other muscle loss-related medical conditions and -stringent cGMP manufacturing requirements."

Mr. Patel continued, "We intend to leverage Forzet's unique value proposition by recommending it as an adjunct solution for patients prescribed GLP-1 agonist drugs via pop-ups through our EinsteinRx hub technology at the point-of-sale in Wellgistics Pharmacy Network pharmacies. Additionally, as we build out our own telehealth customer base where we can more fully service patients through our own Wellgistics Pharmacy both in-store and online, we intend to make GLP-1 drug and related solutions such as Forzet a central feature of our direct-to-consumer (DTC) offering in order to drive loyalty by way of unique product offering as we begin to expand our DTC efforts."

"My practice primarily addresses patients seeking weight loss therapies," said Dr. Vivek Bansal, MD MPH, Triple Board-Certified Endocrinologist and Founder of The EnLyv Clinics in Bridgewater, NJ. "We have been working through myriad products seeking to address muscle loss while on current weight loss therapies, and believe Forzet represents a unique solution that has worked well in other sarcopenia-related medical conditions. We are excited to make this available to our patients."

Dr. Bansal is an independent physician and has not been compensated by Wellgistics for this statement.

The GLP-1 agonist market is expected to grow from $70 billion in 2025 to $201 billion in 2030 ¹ according to Grandview Research. The market growth is driven by drugs with increasing potency to induce weight loss, more convenient oral formulations that help drive adoption as well as increasing interest from non-obese patients looking for weight loss alternatives to diet & exercise. Limiting factors for the expansion of the GLP-1 market include side effects such as muscle loss and gastrointestinal challenges.

Ozempic ^®, Wegovy ^®, and Mounjaro ^® are registered trademarks of their respective owners. Wellgistics Health, Inc. is not affiliated with or endorsed by the manufacturers of these products.

About FORZET ^™[2]

Product Description: Medical Food for the dietary management of muscle loss associated with weight loss therapies.

Classification: "Food for Special Medical Purposes" in accordance with section 5 (b) of the Orphan Drug Act (21 U.S.C. 360ee (b) (3). Nutritional requirement caused by a specific medical condition. For use under medical supervision.

About Wellgistics Health, Inc.

Wellgistics Health (NASDAQ:WGRX) is a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx ^™ into its patented blockchain-enabled smart contracts platform PharmacyChain ^™ to optimize the prescription drug dispensing journey. Its integrated platform connects 6,500+ pharmacies (the "Wellgistics Pharmacy Network") and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment as needed to optimize patient access. Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in the U.S. prescription drug market for independent pharmacies.

For more information, visit www.wellgisticshealth.com.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or the Company's future financial or operating performance and may include, without limitation, statements regarding the anticipated launch, availability, distribution, commercialization and potential adoption of Forzet ^™, the expected benefits of the product, the Company's plans to integrate Forzet into its pharmacy network and telehealth offerings, the development and expansion of the Company's direct-to-consumer initiatives, and the potential growth of the GLP-1 agonist market. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential," "continue," or the negative of these terms or other comparable terminology.

Forward-looking statements are based on current expectations, estimates and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among other things, risks related to the commercialization and market acceptance of the Company's products and services, the Company's ability to successfully expand its pharmacy network and telehealth initiatives, regulatory and compliance considerations relating to medical foods and healthcare products, competition in the healthcare and pharmaceutical distribution markets, changes in market conditions, and other risks and uncertainties described from time to time in the Company's filings with the U.S. Securities and Exchange Commission.

Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. The Company makes no representation that Forzet^™ is intended to diagnose, treat, cure, or prevent any disease.

Wellgistics Media & Investor Contact

Media:
media@wellgisticshealth.com

Investor Relations:
IR@wellgisticshealth.com

¹ https://www.grandviewresearch.com/industry-analysis/glp-1-receptor-agonist-market
² https://tollohealth.com/forzet/

SOURCE: Wellgistics Health, Inc.

View the original press release on ACCESS Newswire

FAQ

What is Forzet and why did Wellgistics (WGRX) launch it on March 9, 2026?

Forzet is a medical food for dietary management of muscle loss associated with GLP-1 therapies. According to the company, it was launched to address muscle loss linked to GLP-1 weight-loss drugs and to support patient adherence and recovery.

Is Forzet an FDA-approved drug and how is it sold by Wellgistics (WGRX)?

Forzet is not an FDA-approved drug; it is classified as a medical food and available over the counter. According to the company, initial distribution is through its affiliated pharmacy and select Wellgistics Pharmacy Network members.

What clinical evidence supports Forzet according to Wellgistics (WGRX)?

According to the company, Forzet's proprietary formulation has been evaluated in multiple controlled clinical studies in Europe. The company cites those studies as supporting its use for sarcopenia-related muscle loss management.

How will Wellgistics (WGRX) promote Forzet to patients prescribed GLP-1 drugs?

Wellgistics plans to use EinsteinRx™ point-of-sale pop-ups and expand DTC telehealth and pharmacy services. According to the company, this intends to drive loyalty and integrate Forzet into GLP-1 therapy workflows.

What GLP-1 market opportunity did Wellgistics (WGRX) reference in the March 9, 2026 announcement?

The company referenced a GLP-1 market expected to grow from $70 billion in 2025 to $201 billion in 2030. According to the company, market growth is driven by more potent drugs and broader patient adoption.